DELCOR Family Office recently backed a AUD$10m funding round of ASX listed AdAlta Limited (ASX:1AD). AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of i-bodies, for treating a wide range of human diseases.
AdAlta is a drug discovery and development company focused on using its proprietary technology platform to generate a new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.
The Initial focus is on treating fibrosis with AdAlta lead fibrosis drug candidate AD-114. This drug is fully funded for phase 1 development of the lead fibrosis drug and i-body.
AdAlta’s new technology platform produces unique proteins known as i-bodies, that mimic the shape of shark antibody binding domain and engineers their key stability features into a human protein, for therapeutic intervention in disease. The single domain antigen binding region of shark antibodies is extremely stable and has a long binding loop not present in either human or next generation antibodies.
1AD share price since listing in August 2016:
Investor Presentation by Managing Director & CEO, Sam Cobb AdAlta InvestorPresentation